STOCK TITAN

Morgan Stanley trims Lantheus (LNTH) ownership to 2.5% of shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Morgan Stanley filed an amended Schedule 13G showing updated ownership in Lantheus Holdings, Inc. common stock as of December 31, 2025. Morgan Stanley reports beneficial ownership of 1,640,837 shares, representing 2.5% of the class, with all voting and dispositive power shared among its reporting units.

Morgan Stanley Capital Services LLC separately reports beneficial ownership of 936,899 shares, or 1.4% of the class, with shared voting and dispositive power. Both reporting persons state they have ceased to be beneficial owners of more than five percent of Lantheus’s common stock and certify that the holdings are in the ordinary course of business and not for influencing control.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.


SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley Capital Services LLC has ceased to be the beneficial owner of more than five percent of the class of securities.


SCHEDULE 13G



Morgan Stanley
Signature:Chris O'Hara
Name/Title:Authorized Signatory, Morgan Stanley
Date:02/12/2026
Morgan Stanley Capital Services LLC
Signature:Chris O'Hara
Name/Title:Authorized Signatory, Morgan Stanley Capital Services LLC
Date:02/12/2026
Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

FAQ

What did Morgan Stanley disclose about its Lantheus (LNTH) ownership?

Morgan Stanley disclosed that it beneficially owns 1,640,837 Lantheus common shares, or 2.5% of the class, as of December 31, 2025. The firm holds only shared voting and dispositive power over these shares through its reporting units.

How much Lantheus (LNTH) stock does Morgan Stanley Capital Services LLC own?

Morgan Stanley Capital Services LLC reports beneficial ownership of 936,899 Lantheus common shares, representing 1.4% of the outstanding class. It has shared voting and shared dispositive power over all these shares, with no sole authority indicated in the filing.

Why did Morgan Stanley file this Schedule 13G/A for Lantheus (LNTH)?

The amended Schedule 13G was filed because Morgan Stanley and Morgan Stanley Capital Services LLC have ceased to be beneficial owners of more than five percent of Lantheus’s common stock. Crossing below the 5% threshold triggers an update to their beneficial ownership report.

Does Morgan Stanley seek to influence control of Lantheus (LNTH)?

The filing states the Lantheus securities were acquired and are held in the ordinary course of business, not to change or influence control of the issuer. It also notes the holdings are not connected with transactions aimed at affecting control, with a limited nomination-related exception.

What level of voting power does Morgan Stanley report in Lantheus (LNTH)?

Morgan Stanley reports zero sole voting power and shared voting power over 1,596,782 Lantheus shares. It also reports shared dispositive power over 1,640,837 shares, meaning decisions about voting and selling are made jointly within its reporting units.

What is the key date referenced in this Lantheus (LNTH) ownership filing?

The key date is December 31, 2025, identified as the date of the event requiring the ownership report. The share amounts and percentage interests disclosed by Morgan Stanley and Morgan Stanley Capital Services LLC are stated as of this date in the filing.
Lantheus Holding

NASDAQ:LNTH

LNTH Rankings

LNTH Latest News

LNTH Latest SEC Filings

LNTH Stock Data

4.56B
64.72M
2.24%
117.27%
11.08%
Drug Manufacturers - Specialty & Generic
In Vitro & in Vivo Diagnostic Substances
Link
United States
NORTH BILLERICA